Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer
— Scorpion receives $65 million from an upfront payment and the achievement of near-term milestones and is eligible to receive up to $553 million in potential milestones, plus royalties on net product sales –
— Scorpion will retain rights to STX-721 and STX-241 in the United States, Canada, and Japan; Pierre Fabre granted rights in all other global territories –
— Collaboration will accelerate development of STX-721 and STX-241 in key international markets and support Scorpion and Pierre Fabre’s missions to bring transformational therapies to patients globally –
BOSTON, Mass. and CASTRES, France – April 04, 2023 – Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, and Pierre Fabre, a French pharmaceutical and dermo-cosmetic group present in 120 countries, today announced an exclusive collaboration and license agreement for the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor (“EGFR”) inhibitors. Discovered by Scorpion, STX-721 and STX-241 are potentially best-in-class inhibitors of EGFR mutations and potent treatment options for emergent and unmet medical needs in non-small cell lung cancer (“NSCLC”). Under the agreement, Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in the United States, Canada and Japan, and Pierre Fabre will be responsible for commercialization activities in all other territories, with a focus on Europe and China. To know more
